Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$126.63 ▲ +4.03
(+3.29%)
MKT CAP: $10.19B • VOL: 1.59M
52W L $56 52W H $130
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$106
MEDIAN
$142
MEAN
$144
HIGH
$172
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KYMR TAPE
KYMR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $153.22 | $145.62 | 2025-02-14 | $115.23 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $159.55 | $149.42 | 2025-02-06 | $119.03 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $144.36 | $139.29 | 2025-01-29 | $121.56 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $129.16 | — | 2025-01-17 | $124.10 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $111.43 | $120.30 | 2025-01-09 | $112.70 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $150.69 | $131.70 | 2024-12-18 | $110.17 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $122.83 | $127.90 | 2024-12-04 | $117.77 | -4.3% | 48% | C |